[go: up one dir, main page]

AR056467A1 - USO DE COMPUESTOS PEPTíDICOS PARA TRATAR DOLOR MUSCULAR - Google Patents

USO DE COMPUESTOS PEPTíDICOS PARA TRATAR DOLOR MUSCULAR

Info

Publication number
AR056467A1
AR056467A1 ARP060103617A ARP060103617A AR056467A1 AR 056467 A1 AR056467 A1 AR 056467A1 AR P060103617 A ARP060103617 A AR P060103617A AR P060103617 A ARP060103617 A AR P060103617A AR 056467 A1 AR056467 A1 AR 056467A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
heterocyclyl
aryl
ethyloxy
group
Prior art date
Application number
ARP060103617A
Other languages
English (en)
Inventor
Bettina Beyreuther
Thomas Stoehr
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of AR056467A1 publication Critical patent/AR056467A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REIVINDICACIoN 1.- Uso de un compuesto que tiene la formula (Ib) donde R es hidrogeno, alquilo inferior, alquenilo inferior, alquinilo inferior, arilo, aril (alquiloinferior), heterociclilo, heterociclil(alquilo inferior), (alquil inferior)heterociclilo, cicloalquilo inferior o (cicloalquil inferior)alquilo inferior, y R está no substituído o está substituído con al menos un grupo aceptor de electrones o/y al menos un grupo dador de electrones; R1 es hidrogeno o alquilo inferior, alquenilo inferior, alquinilo inferior, aril(alquilo inferior), arilo, heterociclil(alquilo inferior), (alquil inferior)heterociclilo, heterociclilo, cicloalquilo inferior, (cicloalquil inferior)alquilo inferior, cada uno no substituído o substituído con al menos un grupo dador de electrones o/y al menos un grupo aceptor de electrones; R2 y R3 son independientemente hidrogeno, alquilo inferior, alquenilo inferior, alquinilo inferior, aril(alquilo inferior), arilo, halo, heterociclilo, heterociclil(alquilo inferior), (alquil inferior)heterociclilo, cicloalquilo inferior, (cicloalquil inferior)alquilo inferior o Z-Y donde R2 y R3 pueden estar no substituído o substituídos con al menos un grupo aceptor de electrones o/y al menos un grupo dador de electrones; y donde en R2 y R3 heterociclilo es furilo, tienilo, pirazolilo, pirrolilo, metilpirrolilo, imidazolilo, indolilo, triazolilo, oxazolilo, isotiazolilo, isoxazolilo, piperidilo, pirrolinilo, piperazinilo, quinolilo, triazolilo, tetrazolilo, isoquinolilo, benzofurilo, benzotienilo, morfolinilo, benzoxazolilo, tetrahidrofurilo, piranilo, indazolilo, purinilo, indolinilo, pirazolindinilo, imidazolinilo, imidazolindinilo, pirrolidinilo, furazanilo, N- metilindolilo, metilfurilo, piridazinilo, pirimidinilo, pirazinilo, piridilo, epoxi, aziridino, oxetanilo, azetidinilo o, cuando N está presente en el heterociclilo, un N-oxido de los mismos; Z es O, S, S(O)a, NR4, NR6' o PR4 o un enlace químico; Y es hidrogeno, alquilo inferior, arilo, aril(alquilo inferior), alquenilo inferior, alquinilo inferior, halo, heterociclilo, heterociclil(alquilo inferior), (alquil inferior)heterociclilo e Y puede estar no substituído o substituído con al menos un grupo dador de electrones o/y al menos un grupo aceptor de electrones, donde heterociclilo tiene el mismo significado como R2 y 3 y con la condicion de que cuando Y es halo, entonces Z es un enlace químico, o Z e Y tomados conjuntamente como ZY son NR4NR5R7, NR4OR5, ONR4R7, OPR4R5, PR4OR5, SNR4R7, NR4SR7, SPR4R5, PR4SR7, NR4PR5R6, PR4NR5R7 o N+R5R6R7, NR4C(:O)-R5, SC(:O)R5, NR4C(:O)-OR5, SC(:O)-OR5, NR4NR5-C(:O)-O R6; R6' es hidrogeno, alquilo inferior, alquenilo inferior o alquinilo inferior que pueden estar no substituídos o substituídos con al menos un grupo aceptor de electrones o/y al menos un grupo dador de electrones; R4, R5 y R6 son independientemente hidrogeno, alquilo inferior, arilo, aril(alquilo inferior), alquenilo inferior o alquinilo inferior, donde R4, R5 y R6 independientemente pueden estar no substituídos o substituídos con al menos un grupo aceptor de electrones o/y al menos un grupo dador de electrones; y R7 es R6 o COOR8 o COR8, pudiendo R7 estar no substituído o substituído con al menos un grupo aceptor de electrones o/y al menos un grupo dador de electrones; R8 es hidrogeno o alquilo inferior, o aril(alquilo inferior), y el grupo arilo o alquilo puede estar no substituído o substituído con al menos un grupo aceptor de electrones o/y al menos un grupo dador de electrones; y n es 1-4; y a es 1-3, o de una sal farmacéuticamente aceptable del mismo, caracterizado, porque dicho uso es para la preparacion de una composicion farmacéutica util para la prevencion, alivio o/y tratamiento de dolor osteoartrítico, tales como hiperalgesia muscular o/y alodinia que ocurren en fibromialgia, síndrome de dolor miofascial, dolor dorsar o/y osteoartritis.
ARP060103617A 2005-08-18 2006-08-18 USO DE COMPUESTOS PEPTíDICOS PARA TRATAR DOLOR MUSCULAR AR056467A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05017977A EP1754476A1 (en) 2005-08-18 2005-08-18 Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US81184006P 2006-06-08 2006-06-08
US81185906P 2006-06-08 2006-06-08

Publications (1)

Publication Number Publication Date
AR056467A1 true AR056467A1 (es) 2007-10-10

Family

ID=35429313

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103617A AR056467A1 (es) 2005-08-18 2006-08-18 USO DE COMPUESTOS PEPTíDICOS PARA TRATAR DOLOR MUSCULAR

Country Status (15)

Country Link
US (2) US20080280835A1 (es)
EP (3) EP1754476A1 (es)
JP (1) JP2009504703A (es)
CN (1) CN101242821A (es)
AR (1) AR056467A1 (es)
AT (1) ATE534379T1 (es)
AU (1) AU2006281591A1 (es)
BR (1) BRPI0614794A2 (es)
CA (1) CA2619545A1 (es)
EA (1) EA014496B1 (es)
ES (1) ES2378244T3 (es)
MX (1) MX2008002293A (es)
TW (1) TW200800147A (es)
WO (1) WO2007020103A2 (es)
ZA (1) ZA200801253B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1243262E (pt) 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
ES2185606T3 (es) 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
ATE428413T1 (de) * 2003-12-02 2009-05-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
CN1950101B (zh) * 2004-04-16 2011-03-30 舒沃茨药物股份公司 肽化合物用于预防和治疗慢性头痛的用途
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EP1781276B1 (en) * 2004-08-27 2010-06-23 UCB Pharma GmbH Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
GB0603008D0 (en) * 2006-02-14 2006-03-29 Portela & Ca Sa Method
EP1920780A1 (en) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
PT2462990E (pt) 2006-06-15 2014-04-02 Ucb Pharma Gmbh Composição farmacêutica com efeito anticonvulsivo sinergístico
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
US8450336B2 (en) * 2006-12-14 2013-05-28 Nps Pharmaceuticals, Inc Use of D-serine derivatives for the treatment of anxiety disorders
US8933065B2 (en) * 2008-04-01 2015-01-13 The University Of North Carolina At Chapel Hill N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
WO2010148300A1 (en) * 2009-06-19 2010-12-23 The University Of North Carolina At Chapel Hill Methods of treatment of neurological disorders
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
US8927602B2 (en) 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
JP5699030B2 (ja) * 2010-07-05 2015-04-08 Ａｘｉｓ株式会社 エタネルセプトを含む線維筋痛症の治療剤
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
EP2646001A2 (en) 2010-12-02 2013-10-09 UCB Pharma GmbH Formulation of lacosamide
US10632087B2 (en) * 2012-02-06 2020-04-28 Innovative Med Concepts, LLC. Famciclovir and meloxicam combination therapy for functional somatic syndromes
EP4328566A1 (en) 2012-10-24 2024-02-28 The Regents of the University of California System for deforming and analyzing particles
WO2017096148A1 (en) * 2015-12-03 2017-06-08 Katz Robert S Methods and systems for diagnosing and treating fibromyalgia
CN109069480A (zh) 2015-12-30 2018-12-21 阿达玛斯医药公司 用于治疗与癫痫相关的病症的方法和组合物
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
MX2023007135A (es) 2020-12-17 2023-08-25 Idexx Lab Inc Detección y tratamiento de la fiebre de las montañas rocosas.
WO2023244864A1 (en) * 2022-06-17 2023-12-21 Spencer Spence Ozone therapeutic treatment apparatus and method of use to treat a treatment location
CN117717539B (zh) * 2023-07-26 2025-01-21 新乡医学院 一种含粪臭素的骨靶向纳米颗粒及其在治疗骨关节炎药物中的应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2937698A1 (de) * 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4533657A (en) * 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr) * 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en) * 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5656267A (en) * 1991-08-22 1997-08-12 Sagen; Jacqueline Implantable cells that alleviate chronic pain in humans
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5536853A (en) * 1994-04-11 1996-07-16 Chiron Corporation Opiate receptor ligands
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
JP3787605B2 (ja) * 1994-10-05 2006-06-21 ダーウィン・ディスカバリー・リミテッド ペプチジル化合物および金属プロテアーゼのインヒビターとしてのその治療的使用
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
WO1997003677A1 (en) * 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US6114390A (en) * 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614542A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
KR100491282B1 (ko) * 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US6048899A (en) * 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
ES2184300T3 (es) * 1997-07-15 2003-04-01 Res Corp Technologies Inc Derivados de aminoacidos utiles para tratar el accidente vascular encefalico.
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6492553B1 (en) * 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
WO2000015223A1 (en) * 1998-09-15 2000-03-23 Eli Lilly And Company Treatment of persistent pain
MXPA02005275A (es) * 1999-12-01 2003-02-17 Ucb Sa Derivado de pirrolidinacetamida solo en combinacion para el tratamiento de trastornos del sistema nervioso central.
ATE301995T1 (de) * 2000-08-17 2005-09-15 Teva Pharma Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
DE60127459T2 (de) * 2000-08-25 2007-07-12 Research Corp. Technologies, Inc., Tucson Verwendung von aminosäurehaltigen Antikonvulsiva zur Behandlung von Schmerz
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
PT1243262E (pt) * 2001-03-20 2006-10-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica
ES2185606T3 (es) * 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
US7183259B2 (en) * 2002-05-17 2007-02-27 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
AR041867A1 (es) * 2002-11-01 2005-06-01 Takeda Pharmaceutical Agente para prevenir o tratar neuropatia
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
WO2004051222A2 (en) * 2002-12-03 2004-06-17 Ucb, S.A. Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
CA2511385A1 (en) * 2002-12-19 2004-07-22 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
JP2006515326A (ja) * 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
US7320675B2 (en) * 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
ATE428413T1 (de) * 2003-12-02 2009-05-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
US20060009384A1 (en) * 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
CN1950101B (zh) * 2004-04-16 2011-03-30 舒沃茨药物股份公司 肽化合物用于预防和治疗慢性头痛的用途
RU2006139930A (ru) * 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) Составы для содействия снижению веса
EP1604654A1 (en) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EP1781276B1 (en) * 2004-08-27 2010-06-23 UCB Pharma GmbH Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
WO2006069293A2 (en) * 2004-12-22 2006-06-29 Friedman Robert S Composition comprising n-acetylcysteine and further pain or anti- inflamm medications
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
PT2462990E (pt) * 2006-06-15 2014-04-02 Ucb Pharma Gmbh Composição farmacêutica com efeito anticonvulsivo sinergístico
US20100260716A1 (en) * 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions

Also Published As

Publication number Publication date
EA014496B1 (ru) 2010-12-30
WO2007020103A2 (en) 2007-02-22
TW200800147A (en) 2008-01-01
EP1754476A1 (en) 2007-02-21
JP2009504703A (ja) 2009-02-05
ES2378244T3 (es) 2012-04-10
WO2007020103A3 (en) 2007-06-07
CA2619545A1 (en) 2007-02-22
MX2008002293A (es) 2008-03-14
AU2006281591A1 (en) 2007-02-22
ATE534379T1 (de) 2011-12-15
BRPI0614794A2 (pt) 2011-04-12
CN101242821A (zh) 2008-08-13
EA200800614A1 (ru) 2008-06-30
US20080280835A1 (en) 2008-11-13
EP2308482A1 (en) 2011-04-13
EP1915140A2 (en) 2008-04-30
EP1915140B1 (en) 2011-11-23
ZA200801253B (en) 2008-12-31
US20070197657A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
AR056467A1 (es) USO DE COMPUESTOS PEPTíDICOS PARA TRATAR DOLOR MUSCULAR
AR049940A1 (es) Uso de compuestos peptidicos para tratar tremor esencial y otros sindromes de tremor
AR061475A1 (es) Compuestos peptidicos para tratar status epilepticus refractario
AR061743A1 (es) Compuestos peptidicos para el tratamiento de trastornos de hiperexcitabilidad y trastornos asociados con disfuncion del canal de hierro
AR050612A1 (es) Novedoso uso de compuestos peptidos para tratar dolor por cancer de huesos, dolor inducido por quimioterapia y nucleosidos y composicion farmaceutica
AR112593A1 (es) Agonistas del receptor tipo toll 7 (tlr7) que tienen una porción heterobiarilo, conjugados de estos y métodos y usos de estos
PE20210140A1 (es) Moduladores de la proteina reguladora de conductancia transmembrana de la fibrosis quistica y metodos de uso
MX2019006411A (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos.
RU2016134258A (ru) Конъюгат лекарственного средства с направляющей молекулой и двумя различными лекарственными средствами
DE602007010781D1 (de) N- (phenylmethyl) -2- (1h-pyrazol-4-yl) acetamid-derivate als p2x7-antagonisten zur behandlung von schmerzen, entzündungen und neurodegeneration
ATE360628T1 (de) Sulfonamide und deren derivate als modulatoren der endothelin-aktivität
EA202090959A1 (ru) Аминзамещенные гетероциклические соединения в качестве ингибиторов ehmt2, их соли и способы их синтеза
EA201401082A1 (ru) Фармацевтические препараты, содержащие антагонисты ccr3
AR113839A1 (es) Antagonistas del receptor b2 de bradiquinina
EA201991511A1 (ru) Кристаллическая структура гремлин-1 и ингибирующее антитело
EA201270266A1 (ru) Гетероциклические соединения
BR112015030331A2 (pt) derivados de succinato
TW200724166A (en) Wrinkle-improving agent
EA201000340A1 (ru) Аминобензилзамещенные циклические сульфоны, полезные в качестве ингибиторов васе
CO2019011969A2 (es) Compuesto de n-(4-piridil)nicotinamida o sal del mismo
AR050098A1 (es) Uso de compuestos peptidicos para tratar dolor en la neuralgia trigeminal
AR050096A1 (es) Uso de compuestos peptidicos para tratar disquinesia
AR050099A1 (es) Uso de compuestos peptidicos para la profilaxis y el tratamiento de dolor de cabeza cronico
AR050097A1 (es) Uso de compuestos peptidicos para tratar dolor en neuropatia diabetica dolorosa
AR050196A1 (es) Uso de compuestos peptidicos para tratar esclerosis lateral amiotrofica

Legal Events

Date Code Title Description
FB Suspension of granting procedure